Arcadia Biosciences, Inc. DEF 14A Filing

TL;DR

<b>Arcadia Biosciences, Inc. files a Definitive Proxy Statement (DEF 14A) on May 16, 2024.</b>

AI Summary

Arcadia Biosciences, Inc. (RKDA) filed a Proxy Statement (DEF 14A) with the SEC on May 16, 2024. Filing is a Definitive Proxy Statement (DEF 14A) filed on May 16, 2024. Company Name: Arcadia Biosciences, Inc. Central Index Key: 0001469443. Standard Industrial Classification: AGRICULTURE PRODUCTION - CROPS [0100]. Business Address: 202 Cousteau Place, Suite 105, Davis, CA 95618.

Why It Matters

For investors and stakeholders tracking Arcadia Biosciences, Inc., this filing contains several important signals. This filing is a standard proxy statement, indicating it's related to shareholder matters such as director elections or executive compensation. The detailed nature of the filing suggests it contains important information for investors regarding corporate governance and financial reporting.

Risk Assessment

Risk Level: low — Arcadia Biosciences, Inc. shows low risk based on this filing. The filing is a routine DEF 14A, which typically contains standard disclosures and does not inherently present new risks.

Analyst Insight

Review the DEF 14A filing for details on executive compensation, director nominations, and any shareholder proposals to understand current corporate governance and potential impacts on investment.

Key Numbers

• 2024-05-16 — Filing Date (DEF 14A filing date)
• 0000950170-24-060967 — Accession Number (Unique identifier for the filing)
• 001-37383 — SEC File Number (SEC's file number for the company)
• 24954690 — Film Number (SEC's film number for the filing)
• 1231 — Fiscal Year End (Company's fiscal year end)

Key Players & Entities

• Arcadia Biosciences, Inc. (company) — Filer name
• 0000950170-24-060967 (other) — Accession Number
• 20240516 (date) — Filing Date
• 0001469443 (other) — Central Index Key
• 0100 (other) — Standard Industrial Classification Code
• DE (other) — State of Incorporation
• 202 COUSTEAU PLACE SUITE 105 (other) — Business Street Address
• Davis (other) — Business City

FAQ

Industry Context

Arcadia Biosciences operates in the agriculture production - crops sector. This DEF 14A filing is related to corporate governance and shareholder matters.

Regulatory Implications

The filing is a DEF 14A, which is a standard SEC form for definitive proxy statements, used to solicit proxies from shareholders.

What Investors Should Do

1. Review the proxy statement for details on director nominees and their qualifications.
2. Examine the executive compensation disclosures, including base salary, bonuses, and stock awards.
3. Identify any shareholder proposals and the company's recommendation for voting.

Year-Over-Year Comparison

This is a DEF 14A filing, which is a routine disclosure for proxy solicitations and does not represent a change from previous filings of the same type.

Filing Documents

• rkda-20240516.htm (DEF 14A) — 1146KB
• img70634337_0.jpg (GRAPHIC) — 28KB
• img70634337_1.jpg (GRAPHIC) — 36KB
• img70634337_2.jpg (GRAPHIC) — 37KB
• img70634337_3.jpg (GRAPHIC) — 537KB
• img70634337_4.jpg (GRAPHIC) — 315KB
• 0000950170-24-060967.txt (&nbsp;) — 4228KB
• rkda-20240516.xsd (EX-101.SCH) — 60KB
• rkda-20240516_htm.xml (XML) — 255KB

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 21

EXECUTIVE COMPENSATION

EXECUTIVE COMPENSATION 24 Processes and Procedures for Compensation Decisions 24 2023 Summary Compensation Table 24 Executive Employment Arrangements 25 Outstanding Equity Awards at Fiscal Year-End 27 Pay Versus Performance 28 EQUITY BENEFIT AND STOCK PLANS 31 LIMITATION OF LIABILITY AND INDEMNIFICATION MATTERS 33 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 35 Policies and Procedures for Related Party Transactions 36 COMMUNICATIONS WITH OUR BOARD OF DIRECTORS 37 AUDIT COMMITTEE REPORT 38 PROPOSAL ONE: ELECTION OF DIRECTORS 39 PROPOSAL TWO: RATIFICATION OF SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTANTS 40 PROPOSAL THREE: APPROVAL OF THE AMENDMENT TO OUR 2015 OMNIBUS EQUITY INCENTIVE PLAN 42 PROPOSAL FOUR: ADVISORY VOTE ON EXECUTIVE COMPENSATION 48 ANNUAL REPORTS 49 OTHER MATTERS 50 APPENDIX A 51 iii ARCADIA BIOSCIENCES, INC. PROXY STATEMENT FOR 2024 ANNUAL MEETING OF STOCKHOLDERS To Be Held at 1:00 p.m. Central Time on Tuesday, June 25, 2024 This proxy statement and the enclosed form of proxy are furnished in connection with the solicitation of proxies by our Board of Directors (the "Board" or "Board of Directors") for use at the 2024 Annual Meeting of stockholders of Arcadia Biosciences, Inc., a Delaware corporation, and any postponements, adjournments or continuations thereof (the "virtual Annual Meeting"). The Annual Meeting will be held virtually on Tuesday, June 25, 2024 at 1:00 p.m. Central Time. References in this Proxy Statement to "we," "us," "our," the "Company" or "Arcadia" refer to Arcadia Biosciences, Inc. The virtual Annual Meeting can be accessed via the internet at www.virtualshareholdermeeting.com/RKDA2024 where you will be able to listen to the meeting live, submit questions, and vote online. The Notice of Internet Availability of Proxy Materials (the "Notice") containing instructions on how to access this Proxy Statement and our Annual Report is

View Full Filing

View this DEF 14A filing on SEC EDGAR